Bluebird Bio is scheduled to resume trading at 1:30 pm ET, with quotation set to resume at 1:25 pm ET, according to Nasdaq. Shares were halted ahead of the company announcing that the U.S. Food and Drug Administration has approved Lyfgenia, also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio reports Q3 EPS 66c, consensus 67c
- BLUE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bluebird Bio to present new and updated data from gene therapy programs at ASH
- Bluebird in pact to sell PRV for $103M with approval of lovo-cel for sickle cell
- Dollar Tree upgraded, Microsoft initiated: Wall Street’s top analyst calls